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Abstract
Background: Simultaneous measurement of gene expression on a genomic scale can be accomplished using
microarray technology or by sequencing based methods. Researchers who perform high throughput gene
expression assays often deposit their data in public databases, but heterogeneity of measurement platforms leads
to challenges for the combination and comparison of data sets. Researchers wishing to perform cross platform
normalization face two major obstacles. First, a choice must be made about which method or methods to employ.
Nine are currently available, and no rigorous comparison exists. Second, software for the selected method must be
obtained and incorporated into a data analysis workflow.
Results: Using two publicly available cross-platform testing data sets, cross-platform normalization methods are
compared based on inter-platform concordance and on the consistency of gene lists obtained with transformed
data. Scatter and ROC-like plots are produced and new statistics based on those plots are introduced to measure
the effectiveness of each method. Bootstrapping is employed to obtain distributions for those statistics. The
consistency of platform effects across studies is explored theoretically and with respect to the testing data sets.
Conclusions: Our comparisons indicate that four methods, DWD, EB, GQ, and XPN, are generally effective, while
the remaining methods do not adequately correct for platform effects. Of the four successful methods, XPN
generally shows the highest inter-platform concordance when treatment groups are equally sized, while DWD is
most robust to differently sized treatment groups and consistently shows the smallest loss in gene detection. We
provide an R package, CONOR, capable of performing the nine cross-platform normalization methods considered.
The package can be downloaded at http://alborz.sdsu.edu/conor and is available from CRAN.
Background
Simultaneous measurement of gene expression on a
genomic scale can be accomplished using microarray
technology or by sequencing based methods [1-3]. Many
high-throughput mRNA expression experiments pro-
duce data that can be of value to other researchers
when analyzed in new contexts or in combination with
data from other experiments. In particular, the statistical
power and reproducibility of gene expression studies
can be increased by combining data across multiple stu-
dies [4-6]. While next generation sequencing seems
likely to replace microarrays for expression analysis in
the near future, the large amount of microarray data
already in existence could continue to be useful to
researchers for many years to come.
Modern microarrays are commercially produced, and
one-color hybridization schemes are often employed.
Several companies have emerged as leading manufac-
turers, each using different manufacturing techniques,
labeling methods, hybridization protocols, probe lengths,
and probe sequences. Table 1 lists some important char-
acteristics of the microarray platforms analyzed in this
work. These characteristics can affect microarray perfor-
mance [7-10]. The length of probes represents a tradeoff
between sensitivity and specificity, with longer probes
being generally more sensitive and shorter being more
specific. The use of linkers to reduce steric hindrance, as
employed by the Applied Biosystems and Illumina plat-
forms in table 1 is one method for increasing the sensitiv-
ity of short probes. The method by which probes are
constructed and attached, and the overall construction of
the array, can affect probe uniformity and intra-platform * Correspondence: faramarz@sciences.sdsu.edu
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the dynamic range of detection.
Chemiluminescence provides greater sensitivity for low
levels of expression compared to fluorescence, but at the
risk of saturation for highly expressed genes. The Applied
Biosystems scanning procedure attempts to mitigate
scanner saturation by using both a short and a long expo-
sure to extend the dynamic range of its expression mea-
surements. Probe sequences affect the binding constants
between probes and target and non-target molecules, and
therefore the sensitivity and specificity of each probe
depends partially on its sequence. Salinity and composi-
tion of the hybridization solution, temperature, and incu-
bation time of hybridization may also affect sensitivity
and specificity. Data from two microarrays are directly
comparable only if those microarrays are identical in all
design parameters including probe sequences and have
been subjected to similar hybridization conditions.
Because no two platforms share the same set of probe
sequences, no two platforms produce data that are
directly comparable, even if all other variables are the
same. For experimenters this restriction is not major.
They need only ensure that all experiments are con-
ducted using the same array platform and protocol. How-
ever, platform effects pose a significant problem for the
re-analysis of data from multiple microarray studies.
Researchers who perform high throughput gene
expression assays often deposit their data in public data-
bases such as ArrayExpress [11] and Gene Expression
Omnibus (GEO) [12], the latter of which currently
houses 630, 845 assays distributed among 9, 348 plat-
forms. Heterogeneity of measurement platforms leads to
challenges for the re-use of these large data sets, creating
limitations for researchers wishing to combine them.
Extensive effort has been directed toward assessing the
reproducibility of differential expression measurements
across different platforms. Several studies have found
good agreement among gene expression profiles pro-
duced by different platforms [13-18], while other studies
have had conflicting results [19-21]. Technical issues per-
taining to such evaluations include homogeneity of RNA
samples, consistency of experimental protocols, mapping
of probes across platforms, and the statistical methods
used to assess reproducibility (e.g. direct comparison vs.
log ratios). Those studies in which good intra-platform
reproducibility was achieved and log ratios were com-
pared across platforms generally showed good inter-plat-
form reproducibility for oligonucleotide-based arrays.
One study focusing on probe mapping in particular
found that reproducibility between Affymetrix and cDNA
platforms could be substantially improved by sequence-
based re-annotation [22], and another found that repro-
ducibility was further improved by mapping probe
sequences at the exon level [14]. More recent studies
generally show better cross-platform reproducibility than
earlier ones [23]. It seems clear that, at least under ideal
conditions, differential expression analysis gives consis-
tent results across platforms. It is therefore worth asking
how data from different platforms might be combined in
an analysis. Models and techniques exist for the meta-
analysis of microarray data from multiple studies and
platforms [24-27], and these have been applied exten-
sively to investigate questions of biological interest
[28-33].
Cross-platform normalization differs from meta-analy-
sis; the former involves direct comparison between
expression measurements obtained from different plat-
forms while the latter combines the results of intra-plat-
form comparisons at a higher level. While meta-
analysis techniques are extremely useful tools, they are
Table 1 Characteristics of relevant microarray platforms
Manufacture Platform Probe
Length
Probe Type Probe Construction Number
of
Probes
Label Type Detection method
Applied
Biosystems
Human Genome
Survey Microarray
v2.0
60 DNA oligonucleotide
with 3’ carbon spacer to
reduce steric effects
Presynthesized and
contact spotted
32878 Digoxigenin
(DIG) UTP
anti-DIG
phosphatase
catalyzed
Chemiluminescence
Affymetrix HG-U133 Plus 2.0
GeneChip
®
25 DNA oligonucleotide In situ photolithography 54675 Biotin phycoerythrin-
streptavidin-
antibody
fluorescence
Agilent Whole Human
Genome Oligo
Microarray, G4112A
60 DNA oligonucleotide In situ inkjet printing 43931 Cy3 or Cy5 Cy3 or Cy5
fluorescence
Illumina Human-6 BeadChip,
48K v1.0
50 DNA oligonucleotide
with 29 base address
sequence as linker
Presynthesized,
immobilized on beads,
and randomly deposited
in wells
47293 Biotin strepatavidin-Cy3
fluorescence
Characteristics of microarray platforms analyzed in this work. See references [7-10] for information sources.
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tested the same hypothesis or compared the same treat-
ments, and can not easily be applied to the investigation
of new hypotheses from existing data.
Cross-platform normalization methods have been
developed for the combination of data sets collected
using different microarray platforms. These methods are
the Cross-Platform Normalization (XPN) method of
Shabalin et al.[34], Distance Weighted Discrimination
(DWD) [35], an Empirical Bayes (EB) method also
known as ComBat [36], Median Rank Scores (MRS)[6],
Quantile Discretization (QD) [6], Normalized Discretiza-
tion (NorDi) [37], the Distribution Transformation (Dis-
Tran) [5], and a method known as Gene Quantiles
(GQ), which was developed as part of the WebArrayDB
service [38]. In addition to these specialized methods,
Quantile Normalization (QN) [39], a method commonly
employed for intra-platform normalization, has also
been applied to cross-platform normalization [40]. Many
of the specialized methods include or are based closely
on QN. Online analysis services currently offering some
of these methods include WebArrayDB [38], ArrayMin-
ing [41], and DSGeo [40]. In addition, QN is available as
part of Bioconductor [42], and code for some methods
can be obtained from their respective authors.
Cross-platform normalization could be a valuable
resource to researchers. While several studies have
employed it for microarray analysis [4-6,43], it has not
achieved the popularity of meta-analysis methods for the
integration of results across studies and platforms. The
online services listed above have received a total of 28
citations as of this writing according Google Scholar. It is
difficult to judge the number of relevant citations for
many methods, as some have alternative uses to cross-
platform normalization or are introduced in publications
describing other techniques. The publication describing
XPN does not introduce any other methods or experi-
ments, nor does XPN have any obvious applications
other than cross-platform normalization. That article has
been cited 34 times since its publication in 2008 accord-
ing to Google Scholar, with only nine of those citing
papers satisfying a full text search for the string “XPN.”
Those wishing to perform cross-platform normalization
face three major obstacles. Firstly, a choice must be made
about which method or methods to employ. While the
authors of each method have demonstrated their meth-
ods on at least one example data set, to our knowledge
no empirical comparison of cross-platform normalization
methods similar to ours is available. In particular, no
third party empirical comparison has been attempted.
The authors of XPN do provide a comparison of their
method against several others [34], but their analysis was
conducted on a more limited data set and does not make
use of resampling or any other procedure to evaluate the
robustness of their results. This is not necessarily a short-
coming of their paper, but merely the result of a differ-
ence in objectives. The authors presented a method, and
it is left for others to provide an unbiased evaluation.
Secondly, software for the selected method must be
obtained and incorporated into a data analysis work-flow.
The disunity of interfaces and software packages for
cross-platform normalization makes this task quite diffi-
cult for researchers lacking advanced computer skills,
especially for methods that are only available as part of
an online service. Some methods also rely on proprietary
software, which presents an additional obstacle to inte-
gration. Thirdly, current cross-platform normalization
techniques are only applicable to a limited subset of data
sets. All the methods listed above require that every
treatment group or sample type be represented on each
platform. If this restriction is violated then it becomes
impossible to distinguish platform effects from treatment
effects of interest, and the latter may end up being
removed by normalization.
In this paper we provide a comparison of available
methods based on the MicroArray Quality Control
(MAQC) project [17] data set and a human sperm data
set [44] containing data from multiple platforms (see
Methods for details). Envisioning potential applications
to large scale databases or classification problems, we
restrict our attention to cross-platform normalization
performed without knowledge of treatment groups, and
we examine the consequences of differently sized and
missing treatment groups for the most successful meth-
ods. We also investigate the consistency of platform
effects across different experiments. We have assembled
an R [45] package capable of performing all of the meth-
ods investigated with a unified interface and reasonable
defaults for user selectable parameters. Our package
makes it possible for researchers to easily incorporate
cross-platform normalization into existing work-flows,
especially work-flows based on R or Bioconductor, and to
experiment with multiple techniques without significant
extra effort. Our package is available from the Compre-
hensive R Archive Network (CRAN, [46]). We explore a
possible solution to the third difficulty above and show
that it is insufficient in some cases.
Results and Discussion
Initial evaluation
As an initial evaluation of the nine cross-platform nor-
malization techniques, we applied each to a subset of the
MAQC data set. Seven assays were selected at random
from each of the four treatment groups, A, B, C, and D,
included in the MAQC experiment from the Illumina
(ILM) and Affymetrix (AFX) platform groups. The result-
ing reduced data set was then subjected to cross-platform
normalization. To visually assess the effectiveness of each
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plots (or sunflower plots for methods with discrete out-
put) were produced for each treatment group and each
normalization method. Figure 1 shows mean-mean plots
for treatment group A. Plots for treatment groups B, C,
and D are included as additional files 1, 2, 3. Because
each treatment group consists of technical replicates, all
points on a mean-mean scatter plot should coincide with
the line y = x under ideal circumstances. The closeness of
the points to that line provides a measurement of inter-
platform concordance. Throughout this work, we have
used the squared Pearson correlation between the x and
y values of these plots, denoted r
2, as a statistical measure
of inter-platform concordance.
Figure 1 Mean-mean plots for MAQC group A ILM and AFX data after cross-platform normalization. Scatter or sunflower plots for MAQC
treatment group A for each normalization method for the ILM and AFX data. Mean expression level of sample A assays on the AFX platform is
plotted against mean expression level on the ILM platform. Plot titles indicate the cross-platform normalization method performed. Red lines are
the line y = x, provided for visual comparison. Sub-titles indicate the r
2 value for the plot.
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methods are ranked by r
2 value as follows: XPN, EB,
DWD, GQ, QN, MRS, DisTran, QD, and NorDi. There is
a substantial gap between the fourth and fifth methods in
the ranking, and another between the eighth and ninth.
To better interpret these plots it is necessary to know the
concordance that can be expected for technical replicates
(replicates in which identical RNA samples were assayed)
within a single platform and for technical replicates
between two platforms. Ideally, the best cross-platform
normalization methods will result in concordance levels
similar to those obtained by technical replicates within a
single platform. Figure 2 shows mean-mean plots for
non-overlapping sets of assays selected from the data set
for each platform, and a mean-mean plot for data from
the two platforms without cross-platform normalization,
for each of the four MAQC treatment groups. Intra-plat-
form concordance is greater than .99 for all treatment
groups and platforms, while inter-platform concordance
is around 0.6 for all treatment groups. Figures 1 and 2
demonstrate that XPN, EB, DWD, and GQ substantially
improve cross-platform concordance, while QN, MRS,
DisTran, and NorDi provide little improvement and in
some cases reduce concordance. The similar shapes dis-
played by the cross-platform scatter plots in Figure 2 sug-
gest a consistency in platform effects among the four
treatment groups. Such platform consistency is explored
later on in this work.
A trivial transformation could be devised to produce
perfect concordance between platforms by the removal
of all platform and treatment effects. However, such a
transformation would be undesirable for cross-platform
analysis because of the loss of treatment effects. To
assess the degree to which treatment effects were
retained during cross-platform normalization, we plotted
Receiver Operating Characteristic (ROC)-like curves for
seven of nine methods for treatment groups A and B
from the reduced MAQC data set (Figure 3). NorDi and
QD were excluded from further analysis because of their
unsatisfactory scatter plots and the additional difficulty
associated with discrete output. A true ROC curve plots
true positives against false positives for a classifier [47].
The ROC-like curves used here show the proportion of
genes classified as differentially expressed as a function
of the estimated false discovery rate (FDR, see Methods
for details). To provide a basis for comparison, we per-
formed differential expression analysis using each plat-
form separately to obtain a native differential expression
set for each platform. An ROC-like curve was obtained
from cross-platform data normalized by each method
(the red curves in Figure 3), along with four additional
curves for comparison. Two curves represent differen-
tially expressed genes detected by either AFX or ILM
(the union of native differential expression sets, yellow
curves in Figure 3) and differentially expressed genes
detected by both AFX and ILM (the intersection of native
differential expression sets, green curves in Figure 3), and
two more represent the intersections of genes detected
by the cross-platform data set with the union (blue) or
intersection (violet) of native differential expression sets
from the individual platforms.
By comparing these curves we obtain statistics for over
and under-detection of differentially expressed genes
after cross-platform normalization as follows. Over-
detection can be assessed by observing the difference
between the ROC-like curve for genes detected with the
cross-platform data set (the red curve) and the curve for
the intersection of the cross-platform genes and the
union of the single platform genes (the blue curve),
which gives the genes detected using the cross-platform
data set but not using either single platform data set.
Under-detection can be assessed by observing the differ-
ence between the curve for the intersection of the two
single platform gene sets (the green curve) and the curve
for the intersection of all three gene sets (the violet
curve), which gives the proportion of genes detected by
both platforms individually but not by the cross-platform
data set. In our further analyses, the areas between these
two pairs of curves are used as statistics to measure over
and under-detection, denoted o and u, respectively, of
differentially expressed genes. These area statistics have
the advantage of not depending on any arbitrary FDR
cut-off, and to our knowledge have not been used
previously.
It is not possible to rank cross-platform normalization
methods by either one of the statistics o or u described
above. For example, a method may bring o to nearly zero
by removing all treatment effects. Such a method would
n o tb ed e s i r a b l e ,a n dw o u l dr e s u l ti nal a r g eu.E a c ho f
the statistics o and u guards against unrestricted optimi-
zation of the other. The o and u statistics are related to
false positive and false negative rates, respectively, and in
practice a good cross-platform normalization should
strike a balance between the two.
Sorted from least to greatest under-detection, the
methods are ordered: DWD, EB, GQ, XPN, MRS, QN,
DisTran. Again, there is a major jump between the fourth
and fifth ranked methods. When sorted instead by over-
detection, the order is: MRS, QN, DisTran, XPN, DWD,
GQ, EB, with a major discrepancy between the third and
fourth ranked methods. Inspection of the ROC-like
curves shows that the lower levels of over-detection
among MRS, DisTran, and QN can be understood in
terms of lower total detection of differentially expressed
genes. By all three measurements, the seven methods
cluster into two groups. The first group, made up of
DWD, EB, GQ, and XPN, is characterized by higher con-
cordance and over-detection and lower under-detection,
Rudy and Valafar BMC Bioinformatics 2011, 12:467
http://www.biomedcentral.com/1471-2105/12/467
Page 5 of 22while the second group, consisting of DisTran, MRS, and
QN, is characterized by lower concordance and over-
detection and higher under-detection. The ROC-like
plots for the two groups are qualitatively different (Figure
3). In the first group, the curve for the cross-platform
normalized data lies between the intersection and union
curves for the native differential expression sets. In the
second group, the curve for the normalized data always
lies below the native intersection curve.
Bootstrapping
Equally sized treatment groups
Figures 1 and 3 provide a qualitative impression of the
effectiveness of each method on the MAQC data set.
For a quantitative assessment, we used the bootstrap to
obtain distributions for the statistics o, u, and r
2, defined
above, for cross-platform normalization between the
AFX and ILM MAQC data. Additionally, we included
MAQC data from the Applied Biosystems (ABI) and
Figure 2 Mean-mean plots for MAQC ILM and AFX data without cross-platform normalization. Scatter plots for each MAQC treatment
group. Single platform plots were produced from random non-overlapping subsets of seven assays each selected from the MAQC data set for
that platform and treatment group. Red lines are the line y = x, provided for visual comparison. Sub-titles indicated the r
2 value for the plot.
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distributions for all three statistics and all six combina-
tions of the four platforms. For all bootstraps, a sample
size of 15 assays was fixed for each treatment group for
a total of 60 assays per bootstrap per platform. Figures
4, 5, and 6 show the distributions of r
2, o, and u, for the
seven non-discrete normalization methods. The XPN
method includes a clustering step, and normalizations
were performed with different clustering options. For
comparison, distributions are also shown for data that
have not been normalized (no.norm) and for resampled
data from each individual platform (resample.1 and
Figure 3 ROC-like curves for the reduced MAQC data set. ROC-like curves for the seven non-discrete cross platform normalization methods
are applied to the reduced MAQC data set. Horizontal axes represent false discovery rate (FDR), while vertical axes represent the proportion of
genes found to be differentially expressed between treatment groups A and B. Horizontal and vertical lines represent the areas used to compute
under-detection (u) and over-detection (o), respectively, although no substantial areas of vertical lines are visible. The “union INT DWD” and
“intersection INT DWD” curves represent the intersections (in the sense of gene sets) of the red curve with the yellow and green curves,
respectively.
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performing an identical experiment again using each
each platform separately. The resampled and non-nor-
malized distributions serve as positive and negative con-
trols, respectively, for successful cross-platform
normalization.
In terms of concordance (Figure 4), results largely
agree with our initial evaluation. Methods can be
divided into the same two groups. The rankings of
DWD, EB, GQ, and XPN fluctuate depending on the
platforms, with one of the XPN methods always show-
ing the highest ranking. XPN, DWD, EB, and GQ all
perform near the level of the resampling controls, while
MRS, QN, and DisTran perform near the level of the
non-normalized cross-platform control. Over detection
(Figure 5) showed the same pattern as in our initial
comparison. We had stated that the reduced over-detec-
tion of MRS, QN, and DisTran may be due entirely to
the reduced level of total detection for those methods.
Here we show that the increased over-detection of XPN,
DWD, EB, and GQ is still below the level of the resam-
pling controls regardless of platform. Under-detection
(Figure 6) was near but somewhat above the resampling
c o n t r o l sf o rX P N ,D W D ,E B ,a n dG Qf o ra l lp l a t f o r m
combinations. MRS, QN, and DisTran fluctuated
together depending on platform, always with a higher
Figure 4 Concordance (r
2) for normalization methods applied to the MAQC data. Plot titles give the source platforms of the data being
normalized. Boxes show the interquartile range and whiskers extend to an additional 1.5 times the interquartile range. Values outside the
whiskers are plotted as circles. Notches are drawn such that non-overlapping notches are strong evidence of differing medians [61,45]. Subtitles
show ranking of the methods. A: resample1, B: resample2, C: dwd, D: eb.par, E: gq, F: mrs, G: qn, H: distran, I: xpn3, J: xpn6, K: xpn9, L: xpn_mod6,
M: no.norm. Inequalities in sub-titles are significant at the 0.5/n
2 level, where n is the number of methods in each sub-figure (including controls),
by two-sided Mann-Whitney U-test. Commas indicate the difference in ranking is not significant. Numbers indicate the number of gene clusters
used for XPN, e.g. xpn6 means XPN was performed using 6 gene clusters.
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level of the negative control. DWD always showed the
lowest level of under-detection, while an XPN variant
was always the highest out of XPN, DWD, EB, and GQ.
Variance of under-detection for the XPN methods
appears markedly higher than for DWD, EB, and GQ. A
Brown-Forsythe Levene-type test based on the absolute
deviations from the median [48] showed the pooled var-
i a n c eo ft h eX P Nm e t h o d sd i f f e r e df r o mt h a to fD W D ,
EB, and GQ at a significance level of less than 1e - 20.
The MAQC data set is unusual in that it contains a
large number of technical replicates. The human sperm
data set contains more biological than technical repli-
cates and is more representative of data sets encountered
in biological research. We performed the same bootstrap-
ping analysis on the AFX and ILM human sperm data
(Figure 7). Again, treatment group sizes were held fixed
at 15 for both platforms for data obtained from both nor-
mal (N) and teratozoospermic (T) individuals. Results for
concordance were similar to the MAQC data set, except
that XPN outperformed the resample controls. All meth-
ods again showed over-detection levels below those of
the resampling controls. DWD again showed the lowest
level of under-detection, followed by GQ and EB. Pre-
vious trials of XPN showed levels similar to those of
MRS, QN, and DisTran when more than 10 gene clusters
were used (results not shown). XPN distributions for
under-detection again showed higher variance than for
Figure 5 Over-detection (o) for normalization methods applied to the MAQC data. Plot titles give the source platforms of the data being
normalized. Boxes show the interquartile range and whiskers extend to an additional 1.5 times the interquartile range. Values outside the
whiskers are plotted as circles. Notches are drawn such that non-overlapping notches are strong evidence of differing medians [61,45]. Subtitles
show ranking of the methods. A: resample1, B: resample2, C: dwd, D: eb.par, E: gq, F: mrs, G: qn, H: distran, I: xpn3, J: xpn6, K: xpn9, L: xpn_mod6,
M: no.norm. Inequalities in sub-titles are significant at the .05/n
2 level, where n is the number of methods in each sub-figure (including controls),
by two-sided Mann-Whitney U-test. Commas indicate the difference in ranking is not significant. Numbers indicate the number of gene clusters
used for XPN, e.g. xpn6 means XPN was performed using 6 gene clusters.
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the 1e - 20 level.
Over all, some results were consistent for all data sets
tested. DWD, EB, GQ, and XPN outperform MRS, QN,
and DisTran in both concordance and under-detection,
with DWD showing the lowest over-detection and XPN
the highest concordance in all cases. Over detection
never exceeded levels observed in resampling controls,
even for the non-normalized control, which in fact
showed no over-detection. Because all treatment groups
were the same size for both platforms, platform effects
would be expected to cancel out when comparing treat-
ment groups. High variance within each treatment group
due to platform effects explains the under-detection seen
in the negative control. The performance of MRS, QN,
and DisTran varied with the data sets tested. MRS, QN,
and DisTran generally performed poorly. However, they
still outperformed the negative control in the sperm data
set, which is consistent with past successful applications
of those methods.
Unequally sized treatment groups
Four cross-platform normalization methods, DWD, EB,
GQ, and XPN, showed satisfactory performance when
evaluated using data sets with balanced treatment group
sizes. Applications in which treatment group sizes are
not consistent across platforms can easily be envisioned.
Figure 6 Under-detection (u) for normalization methods applied to the MAQC data. Plot titles give the source platforms of the data being
normalized. Boxes show the interquartile range and whiskers extend to an additional 1.5 times the interquartile range. Values outside the
whiskers are plotted as circles. Notches are drawn such that non-overlapping notches are strong evidence of differing medians [61,45]. Subtitles
show ranking of the methods. A: resample1, B: resample2, C: dwd, D: eb.par, E: gq, F: mrs, G: qn, H: distran, I: xpn3, J: xpn6, K: xpn9, L: xpn_mod6,
M: no.norm. Inequalities in sub-titles are significant at the .05/n
2 level, where n is the number of methods in each sub-figure (including controls),
by two-sided Mann-Whitney U-test. Commas indicate the difference in ranking is not significant. Numbers indicate the number of gene clusters
used for XPN, e.g. xpn6 means XPN was performed using 6 gene clusters.
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ization methods again using the MAQC data set with
the same bootstrapping procedure. This time only data
from treatment groups A and B were included, and the
number of A and B samples was not necessarily equal
between the two platforms. Five trials were performed
for each method using different combinations of sample
sizes: 15 A, 5 B for AFX and 5 A, 15 B for ILM; 13 A, 7
Bf o rA F Xa n d7A ,1 3Bf o rI L M ;1 0A ,1 0Bf o rA F X
and 10 A, 10 B for ILM; 7 A, 13 B for AFX and 13 A, 7
B for ILM; and 5 A, 15 B for AFX and 15 A, 5 B for
ILM. Results indicate that DWD is the most robust to
sample size differences, but that such differences have
some effect on all methods (Figure 8). The under and
over-detection statistics for XPN responded differently
than for the other methods. Under-detection decreased
for XPN as treatment group size disparity increased,
and over-detection increased. For all other methods, the
opposite was observed. All methods but DWD showed
substantially decreased concordance with increasing
treatment group size disparity. Our modified clustering
procedure reduced this effect in XPN to some extent.
Missing treatment groups
All cross-platform normalization methods studied share a
common strategy. First, a set of parameters is determined
from the data. Those parameters are then used to trans-
form the data to remove platform effects. The parameters
fitted from the data provide an estimate, in one form or
another, of the platform effects present in the data set.
Cross-platform normalization is only possible when all
treatment groups are represented on both platforms.
Otherwise, it becomes impossible to distinguish platform
effects from treatment effects. Relaxation of this restric-
tion would improve the usefulness of cross-platform nor-
malization to researchers wishing to apply it. It may be
possible to overcome this limitation by determining plat-
form effects ahead of time using a separate data set, and
then applying those parameters to the data set one wishes
to transform. This possibility depends on the consistency
of platform effects across different studies and treatment
g r o u p s .T oe v a l u a t ew h e t h e rsuch consistency exists, we
attempted to use parameters derived from the MAQC
data set to perform DWD on the human sperm data set,
first removing all N assays from the AFX data and all T
assays from the ILM data, and then the reverse. DWD
was selected for this experiment because of its success in
previous trials and because of the simplicity of its model
While concordance statistics could not be produced for
this data set because data from each treatment group
w e r er e p r e s e n t e do no n l yo n ep l a t f o r m ,w ew e r ea b l et o
Figure 7 Normalization methods applied to the human sperm AFX and ILM data. Boxes show the interquartile range and whiskers extend
to an additional 1.5 times the interquartile range. Values outside the whiskers are plotted as circles. Notches are drawn such that non-
overlapping notches are strong evidence of differing medians [61,45]. Subtitles show ranking of the methods. Inequalities in sub-titles are
significant at the .05/n
2 level, where n is the number of methods in each sub-figure (including controls), by two-sided Mann-Whitney U-test.
Commas indicate the difference in ranking is not significant. Numbers indicate the number of gene clusters used for XPN, e.g. xpn6 means XPN
was performed using 6 gene clusters.
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the same bootstrapping procedure as before (Figure 9).
Sample sizes were again fixed at 15 for both platforms
and treatment groups. “Self.transfer” indicates that the
human sperm data set, rather than the MAQC, was used
as a training set, which resulted in successful cross-plat-
form normalization. “No.transfer” indicates that the miss-
ing treatments data set was used alone with no additional
training data, which resulted in the removal of all treat-
ment effects. The “Transfer” data set, for which the
MAQC data set was used as a training set, showed over-
detection near the level of non-normalized data, indicat-
ing that the MAQC platform effects, as estimated by
DWD, differ substantially from those of the human
sperm data set. The difference here does not imply that
there is no consistency in the properties of different plat-
forms, but merely that if such consistency exists then
DWD is not sufficient to take advantage of it.
Exploring platform effects
The inconsistency between platform effects in the MAQC
and human sperm data sets may be due to differences in
data processing or experimental protocols. Because of the
age of the human sperm data set, its authors were unable
to give any details regarding their exact procedures. To
further explore the consistency of platform effects for dif-
ferent treatments, we tried using the MAQC A data to
Figure 8 Normalization methods applied to the MAQC data with unequal treatment groups. Labels on the x-axis indicate method names
and the treatment group sizes. Numbers indicate the sizes of treatment groups A and B, respectively, on the AFX platform and B and A,
respectively, on the ILM platform, in terms of number of assays. For example, the label “method.m.n“ indicates that the method “method” was
applied to a data set containing m group A AFX assays, n group B AFX assays, m group B ILM assays, and n group A ILM assays. Boxes show the
interquartile range and whiskers extend to an additional 1.5 times the interquartile range. Values outside the whiskers are plotted as circles.
Notches are drawn such that non-overlapping notches are strong evidence of differing medians [61,45].
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N data to transform the T data. Again we used the same
bootstrapping procedure with 15 assays in each treatment
group. Results (Figure 10) show reduced but high concor-
dance compared to non-normalized data and to
“scrambled” normalization, in which the location para-
meters used by DWD were randomly re-ordered after
being estimated from the training set. Because the data
being transformed contained only one treatment group,
over and under-detection could not be assessed.
Figures 9 and 10 indicate that there is some consistency
in platform effects between treatment groups within the
same study, but possibly less between the MAQC and
human sperm studies. We directly assessed the correlation
between platform effects for different treatments, studies,
and platforms again using DWD. Figure 11 shows correla-
tions obtained between DWD parameters for 16 pairs of
data sets. Each set shows the highest correlation with
resampled data for the same treatment, study, and platform
pair if present, the next greatest with data from a different
treatment and the same study and platform pair, the next
greatest with data from the same platform pair but differ-
ent treatment and study, and the least with data from
another platform pair regardless of treatment and study.
Theoretical perspective
The four best performing methods, DWD, EB, GQ, and
XPN, model platform effects using location parameters,
Figure 9 DWD applied to human sperm data with missing treatment groups. One treatment group was removed from each platform’s
data set before DWD was performed. Subtitles indicate the groups retained. Scrambled: Same as transfer, but parameters were randomly re-
ordered before being used for cross-platform normalization. Self.transfer: Full human sperm data set was used for training. Transfer: MAQC data
set was used for training. No.transfer: No additional training set was used. Boxes show the interquartile range and whiskers extend to an
additional 1.5 times the interquartile range. Values outside the whiskers are plotted as circles. Notches are drawn such that non-overlapping
notches are strong evidence of differing medians [61,45]. Differences between all pairs are significant at the .05/n
2 level, where n is the number
of methods in each sub-figure (including controls), by two-sided Mann-Whitney U-test.
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The representation of platform effect as a location para-
meter is somewhat consistent with a physical interpreta-
tion of the microarray hybridization process. The
hybridization process can be coarsely described by the
chemical equation
p + g
k+

k−
h, (1)
where p, g, and h are the probe, the gene or transcript
target, and the hybridized transcript, respectively, and k+
Figure 10 DWD platform parameter transfer. One treatment group was used as a training set for DWD to transform another treatment group
in the MAQC and human sperm data sets. Titles indicate treatment groups used. Scrambled: Same as transfer, but parameters were randomly re-
ordered before being used for cross-platform normalization. Self.transfer: Full human sperm data set was used for training. Transfer: Indicated
treatment group was used as a training set. No.transfer: No additional training set was used. Boxes show the interquartile range and whiskers
extend to an additional 1.5 times the interquartile range. Values outside the whiskers are plotted as circles. Notches are drawn such that non-
overlapping notches are strong evidence of differing medians [61,45].
Figure 11 Correlations between DWD parameters. DWD parameters were obtained for each treatment group. Bars represent median
correlation values between DWD parameters and whiskers represent interquartile ranges. AFX-ILM A-2 and B-2 represent independent resamples
of the A and B data. Results represent 100 bootstrap iterations.
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centrations, the signal for a hybridized probe at equili-
brium is
S =
Ig0p0
k+
k−
1+ k+
k−g0
, (2)
where S = Ih is measured signal, g0 is the initial con-
centration of target RNA or DNA, p0 is related to the
initial number of available probe sites, and I is related to
the intensity of the marking mechanism associated with
each target DNA or RNA molecule. The parameter I
should be thought of as the intensity of the label on
each target molecule. The number of target molecules
present at the probe site multiplied by the intensity of
each gives the total intensity at that site. Model (2) has
previously been applied to Affymetrix GeneChip
© data
[49,50]. Under this model, the log of the measured sig-
nal is given by
log(S)=l o g ( g0)+l o g

Ip0
k+
k−

− log

1+g0
k+
k−

. (3)
The parameters k+, k-, I, and p0 are determined by the
microarray platform and experimental conditions such
as hybridization temperature. Only g0 is related to gene
expression. Assuming experimental conditions are about
the same for all users of a given platform, a statistical
model of log signal intensity for a particular probe
might be
yijk = Ti + Pj + Cij + εijk, (4)
where yijk is the log signal value for gene i, treatment
j, and repetition k; Ti, Pj,a n dCij are treatment, plat-
form, and treatment-platform interaction effects, respec-
tively; and εijk is a random variable associated with
repetition. Equation (4) is more general than, but fully
consistent with, equation (3). The presence of a treat-
ment-platform interaction term can be tested by analysis
of variance (ANOVA). We performed ANOVA using
model (4) for each gene separately on ABI, AFX, AG1,
and ILM data with treatment groups A, B, C, and D
f r o mt h eM A Q Cd a t as e t ,u s i n gt h el mf u n c t i o no ft h e
R stats package [45]. Figure 12 shows the distribution of
p-values for the null hypothesis (H0)t h a tCij = C for all
treatments and platforms. Using the qvalue package
Figure 12 P-values for ANOVA. Histogram of p-values for treatment-platform interaction terms of model (4).
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π0,f o rw h i c hH0 is true, and subsequently the propor-
tion of genes, π1, for which H0 is false from the distribu-
tion of p-values using the method of Story and
Tibshirani [52]. Results indicate that treatment-platform
interaction effects exist for 93.59% of genes, or about
11, 315 genes out of 12, 091 total. Because not all genes
are differentially expressed, it is to be expected that
some genes show no interaction effect. If there is only
one treatment group, platform and interaction effects
don’t need to be distinguished. Both P and C terms can
be removed by a single location shift. For larger num-
bers of samples, the interaction term cannot be fully
removed by a single location shift. An optimal location
shift, in the least squares sense, for the m treatment
case is
y∗
ijk = yijk − ηj (5)
ηj = Pj +
m
i=1 nijCij m
i=1 nij
(6)
where y∗
ijk is the corrected value and hj is the location
shift used to correct for platform effects. The values nij
are the number of repetitions for treatment i and plat-
form j,a n dm is the total number of different treatment
groups. It is assumed that the true values of the effects
are known. In practice, hj will be an estimate based on
the data.
None of the methods studied here make explicit use
of a least squares optimal location shift to remove plat-
form effects. Rather, this optimal location shift is used
to illustrate the limitations of modeling platform effects
as location parameters under model (1). The prospect of
determining a location shift for a particular pair of plat-
f o r m su s i n go n ed a t as e ta n da p p l y i n gt h a ts h i f tt o
another data set is complicated by the presence of inter-
action effects in equation (6). By equations (5) and (6),
the difference between two treatment group averages in
a two platform data set after the application of a loca-
tion shift derived from another two-platform data set,
assuming equally sized treatment groups, is
¯ y∗
1·· − ¯ y∗
2·· = T1 − T2 +
1
2
2 
i=1
2 
j=1
(−1)
j−1(Cij − C
♦
ij ) (7)
where C
♦
ij are the interaction terms from the training
data set. Depending on the values of Cij and C
♦
ij ,t r a n s -
ference of parameters could result in the increased over-
detection seen in our missing treatment group experi-
ment. Other causes are also possible, including differ-
ences in scanners or image processing procedures.
Uniformity of platform effects across different experi-
ments is consistent with the model (1). Additivity is not,
although empirically it appears to be a useful approxi-
mation, as indicated by the relative success of the loca-
tion based methods. The accuracy of that approximation
may be reduced, however, when employing a separate
training set to estimate platform effects. This reduction
was observed in our analyses, in particular in Figures 9
and 10. Model (1) is a sufficient explanation for all of
our observations, which suggests it or the more general
equation (4) may provide a good basis for an improved
cross-platform normalization method that addresses the
issue of non-identical treatment groups across platforms.
However, fitting such a model would require a data set
containing multiple matched treatment groups for any
pair of platforms on which it could be used.
Software
To facilitate the application of cross-platform normaliza-
tion by other researchers, we packaged all the imple-
mentations used in this work, including those obtained
from other authors, using the R package mechanism.
Our package, CONOR, includes documentation and
provides a common interface for all methods, along
with reasonable defaults for user-selectable parameters.
The package can be downloaded at http://alborz.sdsu.
edu/conor and is available from CRAN.
Conclusions
Of the four methods capable of successful cross-platform
normalization, DWD showed the least loss of treatment
information and XPN showed the greatest inter-platform
concordance, although the latter was sometimes in excess
of resample controls and might be interpreted as a slight
over-correction. DWD was the most robust to variations
in treatment group sizes between the two platforms. This
result is somewhat surprising because XPN incorporates
an assay clustering step designed to correct for such var-
iations [34]. Our clustering variant showed reduced sen-
sitivity to treatment size disparity, and it is possible that
further improvement to the clustering step of the XPN
algorithm could result in improved robustness. It is no
surprise that GQ and EB, which do not account for treat-
ment group disparities, suffered reduced performance
under such conditions. In general, those methods that
employ location shifts (DWD, EB, GQ, and XPN) outper-
formed those that do not, and the performance of the
methods that do not include such shifts was quite unsa-
tisfactory. Many of those methods were not originally
designed for cross-platform normalization, and their fail-
ure to accomplish such normalization does not imply
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XPN methods make use of distributional assumptions
about the data. XPN uses a normally distributed residual
for maximum likelihood estimation, while EB employs a
complicated model including parametric prior distribu-
tions. For the log-transformed microarray data used in
this study, these methods performed well. However, the
distributional assumptions of these methods must be
valid for their performance to be assured. When per-
formed on non-log transformed data, for example, these
methods fail to produce good results. In cases in which
normality is in doubt, appropriate transformations (such
as log transformation) should be employed. Our analyses
considered cross-platform normalization in the absence
of treatment group information. It is possible that super-
ior methods to those investigated could be devised that
make use of treatment information. The EB method is
already able to accommodate treatment group member-
ship information if it is available.
Our experiment in normalizing the human sperm data
set using parameters derived from the MAQC data set
s h o w st h a tt h e r em a yb es o m ec o n s i s t e n c yi np l a t f o r m
effects across different treatments. Larger differences
between platform effects in the MAQC and human
sperm studies may have resulted from differences in
protocols between the two studies. However, they may
also have resulted from larger disparity between gene
expression patterns in sperm and those of other human
tissues, in which case a more complicated model of plat-
form effects might resolve the difference. Ideally, data
sets like the MAQC project’s could be used as “Rosetta
Stones” for gene expression platforms, allowing data col-
lected on one platform to be translated to be compar-
able with data from another platform regardless of
treatment group disparities. This work has shown that a
model including treatment-platform interaction terms
will be required for such a system to be effective, and
further investigation is required before such a system
can be realized.
Next generation sequencing technology is replacing
microarrays for the measurement of gene expression. The
types of platform effects present in microarray data are
probably not relevant for sequencing-based expression
data. Nevertheless, existing databases, as well as microarray
experiments that may be performed in the near future,
represent a substantial resource. Cross-platform normaliza-
tion has the potential to become a valuable tool for gene
expression research by allowing researchers to combine
and analyze existing data together with new data or in new
contexts. While at least nine methods are currently avail-
able, we’ve shown that only four of those methods provide
reasonable results on the MAQC and human sperm data
sets. Although researchers are encouraged to draw their
own conclusions based on their particular needs, two
methods emerged as most effective. In cases in which false
positives are to be preferred over false negatives, or in which
treatment group sizes are not equal for the various single
platform data sets, DWD is the recommended cross-plat-
form normalization method because of its lower under-
detection and improved robustness. In cases in which false
negatives are to be preferred to false positives, and for use
with classifiers, XPN is recommended because of its superior
cross-platform concordance. If there is doubt as to which
situation applies, DWD is recommended, but there is no
reason that multiple techniques could not be employed and
the results compared. The existence of the CONOR pack-
age will make the latter option particularly painless. In
cases in which treatment groups are missing from one plat-
form or another, the DWD-based procedure described
here is the only currently available method, but care must
be taken to ensure that training data have sufficiently simi-
lar transcription profiles to the data being transformed.
Cross-platform normalization of large or complex
datasets in which treatment groups are missing will
require improved models of treatment-platform interac-
tion effects. Future work should include the modifica-
tion of XPN to improve robustness and allow for the
use of a separate training set, as well as the investigation
of other models of platform effects. This study has not
examined every platform available. In particular, no
cDNA arrays were included, and the effectiveness of
cross-platform normalization with such arrays should be
investigated before those methods are applied. While
the types of platform biases present in microarrays are
not relevant to sequencing based assays, it is worth
investigating the effects that different extraction, amplifi-
cation, and sequencing methodologies have of such
measurements, as well as how data from sequencing-
based assays might be combined with microarray data.
W h i l et h ea v a i l a b i l i t yo fa nRp a c k a g ed o e sm u c ht o
make these methods accessible, there are some research-
ers who are not comfortable with the R command-style
interface. For those researchers, a GUI application or
web interface integrating all of those methods may be
beneficial, although web interfaces are already available
for some methods. If the transfer of platform parameters
between data sets is improved, a web-based database of
such platform parameters that could be integrated into
cross-platform analyses would be extremely useful.
Methods
Data preparation
The MAQC data set [17] contains assays of two distinct
RNA samples, Stratagene Universal Human Reference
RNA (treatment group A) and Ambion Human Brain
Reference RNA (treatment group B), along with 3:1
(group C) and 1:3 (group D) mixtures of the two. Each
sample was assayed repeatedly at two or more
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forms used in our analyses were the Applied Biosystems
Human Genome Survey Microarray V2.0, the Affymetrix
HG-U133 Plus 2.0 GeneChip
©, the Agilent Whole Gen-
ome Oligo Microarray G4112A, and the Illumina
Human-6 BeadChip 48k v1.0. These platforms were
selected based on the availability of data and the variety
of probe lengths, manufacturing techniques, and detec-
tion methods employed (see Table 1).
The human sperm data set [44] contains assays of
m R N Af r o ms p e r mo b t a i n e df r o mn o r m a l l yf e r t i l em e n
(group N) and teratozoospermic men (group T), assayed
using the same AFX and ILM arrays as were used in
MAQC, as well as another Illumina array, which was
not used in this study. While some individual samples
were assayed on both the AFX and ILM platforms,
assays in the N or T group of each platform represent
biological rather than technical replicates. Each assay
comes from a unique sample and individual.
The MAQC and human sperm data were obtained from
GEO [GEO: GSE5350 and GSE6969]. The data set for
each microarray platform was subject to different prepro-
cessing. Preprocessing did not make use of treatment
group membership, as such knowledge would not be avail-
able or easily incorporated for some applications. For all
data sets except ABI, quantile normalization was used as
an intra-platform normalization strategy to remove assay
effects. Quantile normalization is a well established and
simple method for intra-platform normalization. While
other methods are available [39], we found quantile nor-
malization to be sufficient for our purposes. All expression
data were subject to log transformation, and it is worth
noting that most cross-platform normalization methods
failed to perform well on data that was not log trans-
formed in our initial trials (results not included). Those
methods that failed to perform on non-log data were
those that employed statistical models, and their poor per-
formance is likely the result of violations of the distribu-
tional assumptions of those models.
Applied Biosystems
The ABI data were downloaded already normalized from
GEO using the GEOquery package [53] from Bioconduc-
tor. These data were normalized by the MAQC authors
using the Expression Array System Software suite from
Applied Biosystems, which implements a platform speci-
fic normalization sequence based on the specific proper-
ties of the ABI array and the 1700 Chemiluminescent
Microarray Analyzer. The steps in this normalization
sequence take advantage of co-localized control probes
and signal to noise ratios obtained during image proces-
sing. Details can be found in the supplemental materials
of the MAQC publication [17] and in the document
entitled “User Bulletin: Applied Biosystems 1700 Chemi-
luminescent Microarray Analyzer” issued by ABI [54].
The downloaded data were natural log transformed
before use in my analyses. It should be noted that the
ABI data set was the only set not subjected to quantile
normalization.
Affymetrix
Raw Affymetrix CEL files were pre-processed using the
function justRMA from the affy package [55] of Biocon-
ductor. For the experiments involving both MAQC and
human sperm data, both sets were normalized together.
For all other experiments, the MAQC and sperm data
were normalized separately.
Agilent
The raw Agilent data were processed using the limma
package [56] from Bioconductor. Background correction
was performed using the “normexp” and “mle” options of
the backgroundCorrect function. Quantile normalization
was performed by the normalizeBetweenArrays function.
Data from duplicate probes was then averaged and nat-
ural log transformation performed.
Illumina
Raw Illumina data were acquired from GEO in text for-
mat. The mean signal for each probe type was extracted
and subjected to quantile normalization (provided by the
normalize. quantiles function from Bioconductor’sp r e -
processCore package) and natural log transformation.
For the experiments involving both MAQC and human
sperm data, both sets were quantile normalized together.
For all other experiments, the MAQC and sperm data
were subjected to separate quantile normalization.
Probe mapping
The MAQC publication [57] provides mappings for all
platforms involved in the study for 12, 091 common
genes as Supplementary Table five, and we used that
mapping for all cross-platform normalization experi-
ments for both the MAQC and human sperm data sets.
T h em a p p i n gw a sa c c o m p l i s h e db yB L A S T i n gp r o b e
sequences against the human RefSeq database. A detailed
BLAST protocol is also provided in the supplementary
materials of the MAQC publication, which are available
from the Nature Biotechnology website. The RefSeq data-
base has been improved and updated since 2006, and
some justification is required for the use of gene annota-
tions that are presently more than four years old. While
it is generally advisable to use the most recent annota-
tions available when analyzing microarray data, little is to
be gained in this case by repeating the mapping with a
more recent version of RefSeq. The number of additional
probes that could be mapped using the current version of
RefSeq is likely to be very small, especially when consid-
ering that the arrays used were designed before the origi-
nal mapping was produced and that the human genome
was already well mapped by 2006. As the purpose of this
study is to compare the various methods for cross-plat-
form normalization, and not to discover genes of
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sufficient.
Plots and statistics
Mean-mean plots and inter-platform concordance
Mean-mean expression scatter plots were produced by
plotting the average expression value for each gene and
treatment group on one platform against the average
expression for the corresponding gene and treatment
group of another platform. Treatment groups for MAQC
data are equivalent to sets of technical replicates (since
the same RNA pool was used for all assays), whereas
treatment groups in the human sperm data set (samples
obtained from normal and teratozoospermic individuals)
represent biological replicates, although some technical
replicates are included. Squared Pearson correlation
between the x and y coordinates of each point in the
mean-mean scatter plot was used as a statistic to measure
inter-platform concordance. It has been pointed out by
the editors that the concordance correlation coefficient is
a more appropriate statistic for these purposes [58].
Unfortunately this error was brought to our attention
after it was possible to make the change. We believe,
however, that the conclusions of this work are not
impacted by the use of the squared Pearson correlation
for two reasons: firstly, that the mean-mean plots used in
this study generally show a good fit to the line y = x,a n d
secondly, that the conclusions drawn are supported by
the other statistics used.
Differential expression and ROC-like curves
Differential expression was assessed using the p-value of
at w o - s i d e dW e l c h ’s t-test as a statistic. A p-value was
obtained for each gene, and the resulting list of p-values
was transformed into a list of q-values using the q-value
package [51], available from Bioconductor. The q-value
for a particular feature (or gene) is defined as the propor-
tion of false positives expected when calling all features
on a list up to and including that one significant, where
here the list in question is the list of p-values obtained
from the t-tests [52]. The empirical cumulative distribu-
tion function (cdf) of the resulting list of q-values is then
equivalent to the ROC-like curves presented. Similar
curves have been used previously in the evaluation of
methods for identifying differentially expressed genes
[57].
The union and intersection curves were obtained by
taking the empirical cdf of the gene-wise minimum and
maximum, respectively, of the two q-value lists. Areas
between curves were obtained by numerical integration
using the trapezoid method, as implemented in the
caTools package [59] available from CRAN. Curves were
sampled at intervals of 0.001 on the FDR axis. Over
detection was measured as the area between the ROC-
like curve for differentially expressed genes detected
using cross-platform normalized data and the intersec-
tion of that curve with the curve representing the union
of genes detected using each platform independently.
Under detection was measured as the area between the
curve representing the intersection of genes detected
using each platform independently and the intersection
of that curve with the curve representing differentially
expressed genes detected using cross-platform normal-
ized data. The sample sizes were equalized for all curves
during the resampling process.
Bootstrapping
A smoothed bootstrapping procedure was used to
obtain distributions for the concordance, over-detection,
and under-detection statistics. The smoothing was
accomplished through the addition of zero-centered
Gaussian noise with a 0.1 standard deviation. Resam-
pling was restricted by treatment groups. That is, for
the MAQC data set, every bootstrap maintained the
same proportion of data from samples A, B, C, and D.
For the human sperm data set, the proportion of data
from N and T samples was kept constant. Data used to
produce the native ROC-like curves for each platform
(and subsequent union and intersection curves) were
produced by the same resampling and smoothing proce-
dure, but with the sample size doubled for the relevant
treatment groups in order to maintain the same total
sample size for each ROC-like curve produced. Data for
resampling (positive) control methods was generated in
the same manner as the data for the native ROC-like
curves, sampled independently to simulate repetition of
the experiment on each platform separately. Computa-
tions were performed using R version 2.9.0 (2009-04-17)
x86_64-redhat-linux-gnu on a Rocks 5.3 computing
cluster. Bootstrapping results are available as additional
file 4.
Cross-platform normalization
R code was obtained for all methods if available. R func-
tions for GQ, MRS, and QD were taken from the source
code for WebArrayDB. Code for EB and NorDi was
obtained from the original authors of those methods.
QN was available from the preprocessCore package of
Bioconductor. To the best of our knowledge, no R
implementations of DWD, DisTran, or XPN existed
prior to this work. Implementation of DisTran was
based on a description of the method [5]. Because the
DisTran method relies on treatment group information,
which for the purposes of this comparison was not con-
sidered to be available, a k-means clustering step was
added to estimate that information. The correct number
of treatment groups was always used as the value of k.
Implementation of DWD and XPN was based on the
Matlab implementations of those methods provided by
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to ensure agreement with the original implementations.
For XPN, agreement was approximate due to the ran-
domness inherent in the initial clustering step. DWD
relies on the solution to a second order cone program
(SOCP). No appropriate SOCP solver existed in R prior
to this work, so a recent smoothing Newton method
algorithm was implemented and employed [60]. Addi-
tional clustering features were added to XPN. In the ori-
ginal Matlab implementation, k-means clustering of
assays was performed on data from both platforms
together. If any cluster contained data from only one
platform, clustering was simply repeated with a different
set of initial centroids. To speed up the clustering pro-
cess, an option to cluster data from the two platforms
separately and match clusters based on the correlation
of cluster centroids was added. XPN trials designated as
“modified” or “mod” made use of this modified method.
Some methods require the user to select one or more
parameters manually. XPN and DisTran both require
the user to select how many assay clusters are to be
used. In all cases, the actual number of treatment
groups was used. XPN also requires the user to select
the number of gene clusters and the number of itera-
tions to perform. Values of 3, 6, and 9 were used for
gene clusters as indicated in the results section. Where
no value is indicated, three gene clusters were used. For
all XPN trials, 30 iterations were performed as recom-
mended by the original authors [34]. The EB method
allows the user to select whether a parametric or non-
parametric prior distribution is to be used. For all trials
shown, the parametric prior was selected. Difficulties
were encountered with the non-parametric option.
NorDi requires the selection of p-value and alpha para-
meters, which were set at 0.01 and 0.05, respectively, in
agreement with that method’s use by its authors.
A detailed description of each method can be found in
the references, with the exception of GQ. GQ is
included as part of the WebArrayDB service [38] and
was invented by the authors of that service, but has
never been described in a publication. GQ is a two step
process. First, the data are transformed by the MRS
method. Second, the median expression value is calcu-
lated for each gene and platform combination in the
MRS normalized data. The median expression values
are then subtracted from the second platform data, and
the first platform’s medians are added to the second
platform’s data set, with the end result that each gene
has the same median expression level on both platforms.
The EB method is capable of taking treatment group
or other covariate information into account [36].
Because we are interested in applications in which such
information may be unavailable, we did not utilize those
capabilities in our analyses.
Additional material
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